Insmed Incorporated Stock Pitch

Abstract

Insmed Incorporated is a biopharmaceutical company out of Bridgewater, New Jersey that specializes in the development and commercialization of therapies and cures for rare and serious diseases. Their key product is called ARIKAYCE and is the only FDA-approved medication that can treat refractory Mycobacterium avium complex (MAC) lung disease. The product is representative of a significant advancement in respiratory care and a commitment by Insmed Incorporated to continue to achieve groundbreaking discoveries in the medical field. Some of Insmed’s other products that are in the works include Brensocatib for bronchiectasis and Treprostinil Palmitil for pulmonary arterial hypertension, both products targeting the market of diseases and conditions that do not yet have a cure. By targeting a relatively untapped market, Insmed has opened more doors within the biopharmaceutical industry, making a name for itself as an attractive investment opportunity.